Saving Time and Money with Transporter Studies

Hosted By: Helen Winsor
03/28/2011
Rate this Podcast: 
Be the first!
To continue viewing this content please fill out the form below and become an Pharma IQ member.
Or if you're already a Pharma IQ member, sign in below to download.
Join

By entering in your information and submitting the form, you give the sponsor permission to contact you regarding their product and you agree to our User Agreement, Privacy Policy, and Cookie Policy.

About this Podcast...

Dominic Surry, Associate Director of In Vitro Screening & Profiling at AstraZeneca, joins Helen Winsor from Pharma IQ, to discuss clinically relevant drug transporters. He explains the importance of exploring and understanding the forthcoming FDA/EMA regulations in order to develop transporter assays and identify transporter substrates, establish IVIVC and evaluate the clinical relevance. During the interview, he predicts which families of transporters will be the most important for drug development; he discusses the critical success factors and common hurdles in studying transporter interactions in the clinical setting; and talks about the importance of pre-clinical transporter data in clinical assessment. Surry also discusses the consequences of not having thorough transporter studies for drug applications, patients and prescribers; and pinpoints where he commonly sees gaps in clinical methodologies for assessing transporter based DDIs – and strategic approaches to bridging these.

EVENTS OF INTEREST

Crowne Plaza Zurich, Zurich, Switzerland
June 17 - 19, 2018